进展报告。一项欧洲随机多中心研究，比较辅助放疗、6个月化疗、联合治疗与不可切除胰腺癌的非辅助治疗（ESPAC-1）。
Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).
作者信息
Neoptolemos J P, Baker P, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Friess H, Büchler M
机构信息
Department of Surgery, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
出版信息
Int J Pancreatol. 1997 Apr;21(2):97-104. doi: 10.1007/BF02822380.
CONCLUSION
The ESPAC-1 trial is the largest study of its kind in pancreatic cancer and should definitively address the question of the role of conventional methods of adjuvant treatment in pancreatic cancer.
BACKGROUND
At the joint International Association of Pancreatology and the European Pancreatic Club meeting in Mannheim, Germany (June 12-15, 1996) a satellite meeting of the European Study Group for Pancreatic Cancer (ESPAC) met to discuss the progress of the ESPAC-1 trial.
METHODS
A randomized multicenter study to address which, if any, of the following adjuvant treatments are of benefit in patients with resectable pancreatic cancer: radiotherapy (40 Gy with 5-FU as a sensitizing agent), 6 mo of chemotherapy (5-FU and folinic acid), or a combination of these treatments.
RESULTS
From February 1994 to June 1996 (the time of the Mannheim meeting) 221 patients so far have been recruited into the three treatment arms and one control arm.
结论
ESPAC - 1试验是同类胰腺癌研究中规模最大的，应能明确解决辅助治疗的传统方法在胰腺癌中作用的问题。
背景
在德国曼海姆举行的国际胰腺病学协会和欧洲胰腺俱乐部联合会议（1996年6月12 - 15日）上，欧洲胰腺癌研究小组（ESPAC）的一次卫星会议召开，讨论ESPAC - 1试验的进展情况。
方法
一项随机多中心研究，旨在确定以下哪些辅助治疗（若有）对可切除胰腺癌患者有益：放疗（40 Gy，使用5 - FU作为增敏剂）、6个月的化疗（5 - FU和亚叶酸）或这些治疗的联合应用。
结果
从1994年2月至1996年6月（曼海姆会议召开之时），到目前为止已有221名患者被纳入三个治疗组和一个对照组。
Zotero 插件